Developmental endothelial locus-1 in cardiovascular and metabolic diseases: A promising biomarker and therapeutic target

Front Immunol. 2022 Nov 28:13:1053175. doi: 10.3389/fimmu.2022.1053175. eCollection 2022.

Abstract

Cardiovascular and metabolic diseases (CVMDs) are a leading cause of death worldwide and impose a major socioeconomic burden on individuals and healthcare systems, underscoring the urgent need to develop new drug therapies. Developmental endothelial locus-1 (DEL-1) is a secreted multifunctional domain protein that can bind to integrins and play an important role in the occurrence and development of various diseases. Recently, DEL-1 has attracted increased interest for its pharmacological role in the treatment and/or management of CVMDs. In this review, we present the current knowledge on the predictive and therapeutic role of DEL-1 in a variety of CVMDs, such as atherosclerosis, hypertension, cardiac remodeling, ischemic heart disease, obesity, and insulin resistance. Collectively, DEL-1 is a promising biomarker and therapeutic target for CVMDs.

Keywords: DEL-1; anti-inflammation; cardiovascular diseases; inflammation resolution; metabolic diseases.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers
  • Cardiovascular Diseases* / drug therapy
  • Cardiovascular Diseases* / etiology
  • Cardiovascular System*
  • Humans
  • Insulin Resistance*
  • Metabolic Diseases* / drug therapy

Substances

  • Biomarkers